 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...186187188189190191192193194195196...235236» |
- |||| Vectibix (panitumumab) / Amgen
Trial completion: PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors (clinicaltrials.gov) - Nov 7, 2017
P2, N=285, Completed, Sponsor: Amgen
Active, not recruiting --> Completed
- |||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open: NALIRICC: Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (clinicaltrials.gov) - Nov 6, 2017
P2, N=100, Recruiting, Sponsor: AIO-Studien-gGmbH
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| New P2 trial, Metastases: PANTHEON: A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy (clinicaltrials.gov) - Nov 6, 2017
P2, N=204, Not yet recruiting, Sponsor: AIO-Studien-gGmbH
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
New P2 trial, Metastases: High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 (clinicaltrials.gov) - Nov 1, 2017
P2, N=90, Recruiting, Sponsor: Shanghai Changzheng Hospital
- ||||| New P1/2 trial: QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Nov 1, 2017
P1/2, N=80, Not yet recruiting, Sponsor: NantKwest, Inc.
- ||| Trial initiation date: QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantKwest, Inc.
Not yet recruiting --> Recruiting Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Sep 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Sep 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=85, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=113, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=79, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| ETBX-061 / ImmunityBio, NK92-CD16-158V / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial initiation date: QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=67, Not yet recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- ||| Trial initiation date: QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Oct 30, 2017
P1/2, N=80, Recruiting, Sponsor: NantKwest, Inc.
Initiation date: Aug 2017 --> Dec 2017 Initiation date: Aug 2017 --> Dec 2017
- | Enrollment change, Trial withdrawal: Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 27, 2017
P1, N=0, Withdrawn, Sponsor: The University of Texas Health Science Center, Houston
Initiation date: Aug 2017 --> Dec 2017 N=24 --> 0 | Recruiting --> Withdrawn
- | New P2 trial: Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial (clinicaltrials.gov) - Oct 26, 2017
P2, N=154, Not yet recruiting, Sponsor: Medical College of Wisconsin
- | Avastin (bevacizumab) / Roche
Biomarker, Enrollment change, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Oct 25, 2017
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=24 --> 0 | Recruiting --> Withdrawn N=2458 --> 3610 | Trial primary completion date: Sep 2010 --> Dec 2017 | N=2458 --> 3610 | Trial primary completion date: Sep 2010 --> Dec 2017
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Surgery, Post-surgery: A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Oct 25, 2017
P2, N=21, Active, not recruiting, Sponsor: NorthShore University HealthSystem
N=2458 --> 3610 | Trial primary completion date: Sep 2010 --> Dec 2017 | N=2458 --> 3610 | Trial primary completion date: Sep 2010 --> Dec 2017 Trial primary completion date: Mar 2017 --> Mar 2018
- | Avastin (bevacizumab) / Roche
Enrollment closed, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=13, Active, not recruiting, Sponsor: Celgene
Trial primary completion date: Mar 2017 --> Mar 2018 Recruiting --> Active, not recruiting
- | Trial initiation date, Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - Oct 25, 2017
P3, N=140, Not yet recruiting, Sponsor: University of Roma La Sapienza
Recruiting --> Active, not recruiting Initiation date: Sep 2017 --> Mar 2018 | Trial primary completion date: Mar 2022 --> Sep 2022
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion, Metastases: AMALTHEA: Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 24, 2017
P2, N=73, Completed, Sponsor: Hellenic Cooperative Oncology Group
Initiation date: Sep 2017 --> Mar 2018 | Trial primary completion date: Mar 2022 --> Sep 2022 Active, not recruiting --> Completed
- |||| Cotellic (cobimetinib) / Exelixis, Roche, tiragolumab (RG6058) / Roche, Tecentriq (atezolizumab) / Roche
Enrollment open, Metastases: MORPHEUS-EC: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) (clinicaltrials.gov) - Oct 24, 2017
P1/2, N=357, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | AMG 337 / ImmunityBio, Amgen
Phase classification, Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer (clinicaltrials.gov) - Oct 19, 2017
P2, N=0, Withdrawn, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Recruiting Phase classification: P1/2 --> P2 | N=308 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Mar 2018
- ||||| numidargistat (INCB001158) / Calithera
New P1/2 trial, Combination therapy, Metastases: A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (clinicaltrials.gov) - Oct 19, 2017
P1/2, N=249, Not yet recruiting, Sponsor: Incyte Corporation
- | Avastin (bevacizumab) / Roche
Enrollment open, Trial primary completion date, Combination therapy, Metastases: VITALITY: Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Oct 18, 2017
P3, N=512, Recruiting, Sponsor: Sun Yat-sen University
Phase classification: P1/2 --> P2 | N=308 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2016 --> Mar 2018 Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018
- ||| spartalizumab (PDR001) / Novartis
Enrollment open, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Oct 18, 2017
P1, N=92, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2017 --> Dec 2018 Not yet recruiting --> Recruiting
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Oct 16, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2017 --> Aug 2013
- | Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Oct 16, 2017
P3, N=2458, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2017 --> Aug 2013 N=3610 --> 2458 | Trial primary completion date: Dec 2017 --> Sep 2010
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Oct 16, 2017
P1, N=42, Recruiting, Sponsor: AstraZeneca
N=3610 --> 2458 | Trial primary completion date: Dec 2017 --> Sep 2010 N=60 --> 42 | Trial primary completion date: Jul 2019 --> Jul 2020
- | Enlituo (cetuximab biosimilar) / Mabpharm Limited, Sorrento
Trial initiation date, Metastases: CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 12, 2017
P3, N=512, Not yet recruiting, Sponsor: Taizhou Mabtech Pharmaceutical Co.,Ltd
N=60 --> 42 | Trial primary completion date: Jul 2019 --> Jul 2020 Initiation date: Aug 2017 --> Dec 2017
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Oct 11, 2017
P1, N=79, Active, not recruiting, Sponsor: University of Chicago
Initiation date: Aug 2017 --> Dec 2017 Recruiting --> Active, not recruiting | N=45 --> 79 | Trial primary completion date: Sep 2017 --> Aug 2018
- | leucovorin calcium / Generic mfg.
Enrollment closed, Trial primary completion date: ACTHYF: Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children (clinicaltrials.gov) - Oct 10, 2017
P3, N=175, Active, not recruiting, Sponsor: Institut Jerome Lejeune
Recruiting --> Active, not recruiting | N=45 --> 79 | Trial primary completion date: Sep 2017 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017
- pyrimethamine / Generic mfg.
Enrollment open: Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - Oct 10, 2017
P1, N=12, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- || napabucasin (BBI608) / Sumitomo Pharma
Enrollment closed, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (clinicaltrials.gov) - Oct 9, 2017
P1, N=250, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| napabucasin (BBI608) / Sumitomo Pharma
Enrollment closed, Combination therapy, Metastases: A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Oct 9, 2017
P1/2, N=609, Active, not recruiting, Sponsor: Boston Biomedical, Inc
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Oct 9, 2017
P1b, N=9, Active, not recruiting, Sponsor: Oncolytics Biotech
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2017 --> Jan 2018
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis
Trial primary completion date, Tumor cell: Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas (clinicaltrials.gov) - Oct 7, 2017
P=N/A, N=19, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Sep 2017 --> Jan 2018 Trial primary completion date: Jul 2017 --> Aug 2018
- | Avastin (bevacizumab) / Roche
Enrollment open, Trial initiation date: CLavSyn: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (clinicaltrials.gov) - Oct 6, 2017
P2, N=177, Recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
Trial primary completion date: Jul 2017 --> Aug 2018 Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017
- | Avastin (bevacizumab) / Roche
New P3 trial, Metastases: A Study of 2nd-line FOLFIRI (clinicaltrials.gov) - Oct 5, 2017
P3, N=280, Recruiting, Sponsor: Sun Yat-sen University
- || 5-fluorouracil / Generic mfg., cisplatin / Generic mfg., docetaxel / Generic mfg.
Trial primary completion date: Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 4, 2017
P2, N=111, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting | Initiation date: Apr 2017 --> Aug 2017 Trial primary completion date: Oct 2017 --> Oct 2018
- | Trial primary completion date: Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial (clinicaltrials.gov) - Oct 3, 2017
P3, N=15, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2017 --> Oct 2018 Trial primary completion date: Jan 2013 --> Jul 2011
- crenolanib (ARO-002) / AROG
Trial completion, Trial primary completion date, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Oct 3, 2017
P1, N=10, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jan 2013 --> Jul 2011 Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Oct 2016
- |||||||||| Vectibix (panitumumab) / Amgen
New P3 trial: 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab (clinicaltrials.gov) - Oct 3, 2017
P3, N=450, Not yet recruiting, Sponsor: University of Southern California
- | Imlygic (talimogene laherparepvec) / Amgen
New P1 trial, Surgery, Metastases: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer (clinicaltrials.gov) - Oct 3, 2017
P1, N=21, Recruiting, Sponsor: National Cancer Institute (NCI)
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open, Metastases: BTCRC-GI15-015: FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (clinicaltrials.gov) - Oct 1, 2017
P2, N=39, Recruiting, Sponsor: Al B. Benson, III, MD
Active, not recruiting --> Completed | Trial primary completion date: Nov 2017 --> Oct 2016 Not yet recruiting --> Recruiting
- | Trial primary completion date: FOLFIRINOX + RT for Pancreatic Cancer (clinicaltrials.gov) - Sep 29, 2017
P2, N=50, Active, not recruiting, Sponsor: Massachusetts General Hospital
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2018 --> Mar 2017
- |||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) (clinicaltrials.gov) - Sep 28, 2017
P3, N=800, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2018 --> Mar 2017 Not yet recruiting --> Recruiting
- | oxaliplatin / Generic mfg.
New P1/2 trial: PIPOX: Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers (clinicaltrials.gov) - Sep 27, 2017
P1/2, N=50, Recruiting, Sponsor: Institut Cancerologie de l'Ouest
- | Avastin (bevacizumab) / Roche
Biomarker: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Sep 25, 2017
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017